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Summary
Background.— Hypertrophic cardiomyopathies (HCM) are often associated with left ventricular
(LV) outﬂow tract obstruction, which can explain symptoms and impact prognosis.
Aims.— To better understand the mechanisms that link obstruction and LV shape in HCM.
Methods.— Patients with HCM who underwent cardiac magnetic resonance (CMR) imaging
were included retrospectively. Obstructive HCM was deﬁned as LV outﬂow gradient more than
30mmHg at rest by transthoracic echocardiography. The LV shape and mitral angle were assessed
by CMR. Results were compared with control subjects.
Results.— Mean LV-mitral angle was smaller in patients with obstructive HCM (n = 29) than
in patients with non-obstructive HCM (n = 15) or control subjects (n = 15) (80± 5◦ vs 87± 7◦
[P = 0.0002] and 89± 2◦ [P < 0.0001]). Mean mitral papillary muscles angle was greater in patients
with non-obstructive HCM than in patients with obstructive HCM or control subjects (136± 17◦ vs
123± 16◦ [P = 0.007] and 118± 10◦ [P = 0.002]). Patients with non-obstructive HCM had a greater
mean LV-aortic root angle than patients with obstructive HCM or control subjects (139± 6◦ vs
135± 7◦ [P = 0.04] and 133± 7◦ [P = 0.03]).
Conclusion.— There is a relation between morphological and functional parameters in HCM
within which the mitral valve is probably part of pathophysiogenesis.
© 2013 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— Les cardiomyopathies hypertrophiques (CMH) sont souvent associées à une obstruc-
tion intraventriculaire gauche qui peut expliquer les symptômes et modiﬁer le pronostic.
Objectif.— Mieux comprendre les mécanismes qui relient l’obstruction intraventriculaire et la
géométrie ventriculaire dans la CMH.
Méthodes.— Les patients porteurs d’une CMH et ayant été explorés par imagerie par réso-
nance magnétique (IRM) cardiaque ont été rétrospectivement inclus. La CMH obstructive était
déﬁnie par un gradient intraventriculaire gauche supérieur à 30mmHg au repos en échocardio-
graphie transthoracique. La géométrie ventriculaire gauche et l’angle de la valve mitrale avec
le ventricule gauche ont été explorés par IRM. Les résultats ont été comparés à ceux de sujets
témoins.
Résultats.— L’angle mitral moyen était plus petit chez les patients porteurs d’une CMH obstruc-
tive (n = 29) que chez les patients porteurs d’une CMH non obstructive (n = 15) ou chez les sujets
témoins (n = 15) (80± 5◦ contre 89± 2◦ [p < 0,0001] et 87± 7◦ [p = 0,0002]). L’angle interpapil-
laire moyen était plus important chez les patients porteurs d’une CMH non obstructive que
chez les patients porteurs d’une CMH obstructive ou chez les sujets témoins (136± 17◦ contre
123± 16◦ [p = 0,007] et 118± 10◦ [p = 0,002]). Les patients porteurs d’une CMH non obstructive
avaient un angle aortique moyen plus grand que les patients porteurs d’une CMH obstructive
ou que les sujets témoins (139± 6◦ contre 135± 7◦ [p = 0,04] et 133± 7◦ [p = 0,03]).
Conclusion.— Il existe une relation entre les paramètres morphologiques et fonctionnels du
myocarde dans la CMH, dans laquelle la valve mitrale intervient probablement dans la phys-
iopathologie.
© 2013 Elsevier Masson SAS. Tous droits réservés.
Background
Hypertrophic cardiomyopathy (HCM) is a relatively common
genetic cardiac disease with a prevalence of 1/500 [1] and
a heterogeneous phenotype. Left ventricular (LV) outﬂow
tract obstruction is of great concern in the exploration and
management of HCM because of the association with poor
outcome and symptoms [2]. Mechanisms that underlie the
obstruction are complex and require special LV hypertrophy
and systolic anterior motion of the anterior leaﬂet of the
mitral valve. After several years dedicated to the descrip-
tion of abnormal myocardium, including LV hypertrophy and
LV outﬂow tract, the emergence of new imaging techniques
now allows the role of the mitral apparatus in the genesis of
LV outﬂow tract obstruction to be highlighted [3—8]. Abnor-
malities of the mitral valve have previously been described,
including increased mitral leaﬂet areas, decreased mobil-
ity of the posterior mitral leaﬂet, increased numbers and
mass of papillary muscles and abnormal positions of pap-
illary muscles [3—8]. Providing a good contrast and a high
spatial resolution, cardiac magnetic resonance (CMR) imag-
ing allows a precise assessment of LV geometry and mitral
apparatus [9,10]. The purpose of our work was to study the
relation between left ventricular shape, mitral valve angle
and left ventricular outﬂow tract obstruction at rest using
CMR.
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Methods
Sample
We retrospectively studied 44 consecutive patients with HCM
who underwent CMR between January 2006 and February
2012 in the Cardiac Imaging Centre at Rangueil Univer-
sity Hospital, Toulouse, France. The clinical diagnosis of
HCM was based on the demonstration by bi-dimensional
echocardiography of a non-dilated and hypertrophied left
ventricle (maximum left wall thickness≥ 15mm) in the
absence of another cardiac or systemic disease that could
produce a similar degree of hypertrophy [11—13]. During
the same period, 15 control subjects without cardiomy-
opathy were retrospectively recruited from consecutive
referrals to our Cardiac Imaging Centre for persantin CMR
to detect silent myocardial ischaemia. Any patients with
clinical evidence of coronary artery disease were excluded,
including patients with a clinical history and typical elec-
trocardiogram associated with biochemical, angiographic or
CMR evidence of previous myocardial infarction. Patients
with a positive stress magnetic resonance imaging (MRI)
test were also excluded. Demographic data, cardiovascular
risk factors and medications were extracted from medical
records.
Echocardiography
Transthoracic bi-dimensional echocardiography was per-
formed using the commercially available system Philips
IE33 (Philips Healthcare, Best, The Netherlands). The
peak instantaneous LV outﬂow tract gradient was mea-
sured at rest with continuous-wave Doppler in the apical
ﬁve-chamber view with the simpliﬁed Bernoulli equation.
Obstructive HCM was deﬁned by a peak instantaneous LV
outﬂow gradient greater or equal to 30mmHg at rest
[2,14].
Cardiovascular magnetic resonance
CMR (Siemens Avanto 1.5-T, Erlangen, Germany, n = 25 and
Philips Intera 1.5-T, Eindhoven, The Netherlands, n = 19)
was performed using cine steady-state free precession
breath-hold sequences (echo time [TE]/repetition time
[TR] = 1.5/25ms, ﬂip angle 80◦, matrix 192× 156, ﬁeld
of view= 350× 350mm, temporal resolution 35ms for the
Siemens scan; and TE/TR = 1.5/3.5ms, ﬂip angle 60◦, matrix
160× 146, ﬁeld of view 350× 350mm, temporal resolution
35ms for the Philips scan) in four-chamber, long-axis and
LV outﬂow track views; and sequential 8-mm short-axis
views (no gap) from the atrioventricular ring to the apex.
The late gadolinium enhancement images were acquired
10minutes after intravenous gadolinium-diethylenetriamine
pentaacetic acid (0.2mmol/kg) in identical short-axis planes
using an inversion-recovery gradient echo sequence. Inver-
sion times were adjusted to null normal myocardium
(typically 320—440ms). In all patients, imaging was
repeated for each short-axis image in two separate phase-
encoding directions to exclude artefacts. Late gadolinium
enhancement was assessed visually and was only deemed
to be present when the area of signal enhancement could
be seen in a cross-cut long-axis image by the independent
observers.
Ventricular volumes and function were measured using
standard techniques and analysed using semi-automated
software (Argus software, Siemens, Erlangen, Germany
and ViewForum software, Philips, Eindhoven, The Nether-
lands). LV mass was indexed to body surface area.
LV shape and mitral angles were measured in end-
diastole at rest using the open source software Osirix
(http://www.osirix-viewer.com). The LV-mitral angle (LVMa)
was deﬁned as the angle between the LV axis and the mitral
annulus in the four-chamber view (Fig. 1A, left panel).
The mitral papillary muscles angle (MPMa) was deﬁned as
the angle between the middle of the base of both mitral
papillary muscles and the centre of the left ventricle in
the LV short-axis view (Fig. 1B, left panel). As previously
described, the LV-aortic root angle (LVARa) was deﬁned as
the angle between the LV inﬂow and outﬂow tract by trac-
ing a line between the apex and the middle of the mitral
annulus and a line passing through the long axis of the
aortic root in the three-chamber view [15] (Fig. 1C, left
panel).
Statistical analysis
Baseline characteristics are summarized using means and
standard deviations (SDs) for continuous variables, and num-
bers and percentages for categorical variables. Associations
between categorical variables were investigated using the
Fisher’s exact test; and the mean values of continuous varia-
bles were compared using a Mann-Whitney test. Spearman’s
correlation co-efﬁcient was used to assess the association
between angles and peak instantaneous LV outﬂow tract gra-
dients. Reproducibility was assessed in 10 randomly selected
patients and expressed as the absolute difference between
two paired measurements divided by their average. The sta-
tistical difference was considered to be signiﬁcant when
P-values were < 0.05. All analyses were performed using
Statview (SAS Institute Inc., Version 5).
Results
Population
Among the 44 patients with HCM explored by CMR imag-
ing between January 2006 and February 2012, 24 (55%)
were men and the mean age was 55± 15 years. Of these
44 patients, 29 (66%) had LV outﬂow tract obstruction at
rest (mean peak instantaneous LV outﬂow tract gradient
62± 57mmHg). All of the patients with obstructive HCM
had a systolic anterior motion of the mitral valve. Among
the 15 patients without LV outﬂow tract obstruction, two
(5%) patients had peak instantaneous LV outﬂow tract gra-
dients of 12 and 18mmHg at rest. The other patients
without LV outﬂow tract obstruction had no gradient at
rest. The mean indexed LV mass of all 44 patients was
95± 27 g/m2. Thirty-four patients (77%) with HCM had symp-
toms: 21 (48%) and 13 (30%) of patients were New York
Heart Association (NHYA) stages II and III, respectively. HCM
patients and control subject characteristics are shown in
Table 1.
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Figure 1. Right: cardiac magnetic resonance (CMR) images of the (A) angle between the left ventricle and the mitral annulus plane (LVMa),
(B) interpapillary muscle angle (MPMa) and (C) angle between the left ventricle and the aortic root (LVARa). Left: box-whisker plots of the
(A) angle between the left ventricle and the mitral annulus plane (LVMa), (B) interpapillary muscle angle (MPMa) and (C) angle between the
left ventricle and the aortic root (LVARa) in control subjects and patients with non-obstructive hypertrophic cardiomyopathy (NOHCM) and
obstructive hypertrophic cardiomyopathy (OHCM). The boxes show the ﬁrst and third percentiles; the line shows the median; the whiskers
show 95 percentiles and the circles are outliers. *P < 0.05 vs NOHCM. **P < 0.01 vs NOHCM; ***P < 0.001 vs non-obstructive HCM; †P < 0.05 vs
controls; ††P < 0.01 vs controls; †††P < 0.001 vs controls.
Relation between LV shape and LV outﬂow
tract obstruction
LVMa, MPMa and LVARa for control subjects, non-obstructive
and obstructive HCM are shown in Table 2 and Fig. 1.
LVMa was signiﬁcantly smaller in patients with obstruc-
tive HCM than in patients with non-obstructive HCM
or the control subjects (80± 5◦ vs 87± 7◦ [P = 0.0002]
and 89± 2◦ [P < 0.0001], respectively). There was no
signiﬁcant difference for LVMa between patients with non-
obstructive HCM and the control subjects (P = 0.27). MPMa
was greater in patients with non-obstructive HCM than
in patients with obstructive HCM and control subjects
(136± 17◦ vs 123± 16◦ [P = 0.007] and 118± 10◦ [P = 0.002],
respectively). There was no signiﬁcant difference for MPMa
between patients with obstructive HCM and control subjects
(P = 0.33). Patients with non-obstructive HCM had greater
LVARa than patients with obstructive HCM or control sub-
jects (139± 6◦ vs 135± 7◦ [P = 0.04] and 133± 7◦ [P = 0.03],
respectively). There was no signiﬁcant difference for LVARa
between patients with obstructive HCM and control subjects
(P = 0.6).
Considering the overall population of patients with HCM,
there were signiﬁcant inverse correlations between the peak
instantaneous LV outﬂow tract gradient at rest and LVMa and
MPMa, but not with LVARa (Fig. 2).
The intra- and inter-observer variabilities of the angle
measurements, as shown in Table 3, were good.
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Table 1 Healthy control subjects’ and hypertrophic cardiomyopathy (HCM) patients’ characteristics.
Control subjects
(n = 15)
Non-obstructive HCM
(n = 15)
Obstructive HCM
(n = 29)
Age (years) 53± 14 50± 17 57± 14
Men 13 (87) 9 (60) 15 (52)†
Body mass index (kg/m2) 26± 3 26± 4 27± 4
NYHA functional class 1.1± 0.4 1.8± 1.0 2.2± 0.6†††
NYHA class
I 13 (87) 7 (47)† 3 (10)†††,*
II 2 (13) 3 (20) 18 (62)††,*
III/IV 0 5 (33)†† 8 (28)†
Family history of HCM 0 5 (33)†† 4 (14)
Maximum LV thickness (mm) 10± 2 21± 7††† 21± 4†††
Indexed LV mass (g/m2) 62± 17 92± 18††† 97± 31†††
Late gadolinium enhancement 0 14 (93)††† 12 (41)††,***
LVEF (%) 62± 10 63± 7 69± 8†
Medical history
Smoking habit 1 (7) 0 2 (7)
Hypertension 6 (40) 3 (20) 7 (24)
Diabetes 1 (7) 3 (20) 2 (7)
Hyperlipidaemia 3 (20) 4 (27) 9 (31)
Medications
Diuretic 3 (20) 6 (40) 10 (34)
ACEI or ARB 5 (67) 4 (27) 7 (24)
Beta-blocker 3 (20) 11 (73)†† 28 (97)†††,*
Calcium channel blocker 1 (7) 2 (13) 3 (10)
Data are expressed as n (%) or mean± standard deviation. ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor
blocker; HCM: hypertrophic cardiomyopathy; LV: left ventricular; LVEF: left ventricular ejection fraction; NYHA: New York Heart
Association.
*P < 0.05 vs non-obstructive HCM.
**P < 0.01.
***P < 0.001 vs non-obstructive HCM.
† P < 0.05 vs controls.
†† P < 0.01 vs controls.
††† P < 0.001 vs controls.
Table 2 LV-mitral angle, mitral papillary muscles angle and LV-aortic root angle for healthy control subjects and non-
obstructive and obstructive hypertrophic cardiomyopathy (HCM) patients.
Controls
(n = 15)
Non-obstructive
HCM (n = 15)
Obstructive
HCM (n = 29)
LVMa (◦) 89 ± 2 87 ± 7 80 ± 5†††,***
MPMa (◦) 118 ± 10 136 ± 17†† 123 ± 16**
LVARa (◦) 133 ± 7 139 ± 6† 135 ± 7*
Data are expressed as mean± standard deviation. ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker;
HCM: hypertrophic cardiomyopathy; LV: left ventricular; LVARa: LV-aortic root angle; LVEF: left ventricular ejection fraction; LVMa:
LV-mitral angle; MPMa: mitral papillary muscles angle; NYHA: New York Heart Association.
* P < 0.05 vs non-obstructive HCM.
** P < 0.01 vs non-obstructive HCM.
*** P < 0.001 vs non-obstructive HCM.
† P < 0.05 vs controls.
†† P < 0.01 vs controls.
††† P < 0.001 vs controls.
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Figure 2. Correlations between left ventricular (LV) outﬂow tract
obstruction at rest and (A) LV-mitral angle (LVMa), (B) mitral pap-
illary muscles angle (MPMa) and (C) LV-aortic root angle (LVARa) in
patients with hypertrophic cardiomyopathy (HCM).
Table 3 Intra- and inter-observer variability.
Intra-observer
variability
Inter-observer
variability
LVMa 0.05 ± 0.02 0.07 ± 0.07
MPMa 0.06 ± 0.04 0.10 ± 0.05
LVARa 0.05 ± 0.04 0.05 ± 0.03
Data are expressed as mean± SD. Variability is expressed as
the ratio between the difference between and the mean of
two independent readings. LVARa: LV-aortic root angle; LVMa:
LV-mitral angle; MPMa: mitral papillary muscles angle.
Relation between LV shape and late
gadolinium enhancement
Considering patients with HCM, there was no difference in LV
shape according to the presence or absence of late gadolin-
ium enhancement, with respective values of 84◦ and 80◦
(P = 0.24) for LVMa, 128◦ and 126◦ (P = 0.75) for MPMa, and
136◦ and 136◦ (P = 0.91) for LVARa.
Discussion
Our study shows that the angle between the mitral annu-
lus plane and the left ventricle is signiﬁcantly smaller in
patients with obstructive HCM than in those with non-
obstructive HCM. Furthermore, for the ﬁrst time, we have
shown that there is an inverse correlation between the
angle of the mitral annulus plane with the left ventri-
cle and the peak instantaneous LV outﬂow tract gradient
at rest. We have also shown that the presence of late
gadolinium enhancement does not impact the LV shape in
patients with HCM. This is the ﬁrst study to prove the exist-
ence of a different angle of the mitral annulus plane with
the left ventricle between obstructive and non-obstructive
HCM. Previous echocardiographic studies have shown abnor-
malities of anatomy and motion of the mitral valve in
obstructive HCM, especially by elongation of mitral leaﬂets
and increased leaﬂet areas [3,16—19]. These results sug-
gest the association of a defect in the coaptation of mitral
leaﬂets and an excess of valvular tissue to generate a sys-
tolic anterior motion of the mitral valve and then LV outﬂow
tract obstruction. Recently, Maron et al. conﬁrmed these
ﬁndings with an MRI study in a large cohort of patients and
showed that the elongation of mitral leaﬂets is the pri-
mary phenotypic expression of HCM [4]. Their results suggest
that mitral valve abnormalities could be the ﬁrst step of
LV outﬂow tract obstruction in HCM. In our study, we have
conﬁrmed the relation between mitral apparatus and LV out-
ﬂow tract obstruction in showing that the angle between the
mitral annulus plane and left ventricle in patients with non-
obstructive HCM is the same as for healthy control subjects.
In light of previous results from Maron et al. [4], our results
suggest that LV outﬂow tract obstruction in patients with
HCM is linked with mitral apparatus geometry but not with
LV hypertrophy.
The question of the role of papillary muscles in LV
outﬂow tract obstruction in HCM remains unresolved. Sev-
eral studies have shown that mitral subvalvular structures
and particularly papillary muscles are structurally differ-
ent in patients with HCM than in healthy controls. An MRI
study has described an increase in the number and mass
of papillary muscles in HCM patients [7]. Previous two-
and three-dimensional echocardiography studies showed
abnormalities of papillary muscle insertions and mobility
in patients with obstructive HCM. These studies showed an
anterior displacement of both papillary muscles [5,19] with
direct insertion of the anteromedial papillary muscle on the
anterior mitral leaﬂet [3] compared with patients with non-
obstructive HCM. In our study, we have demonstrated that
the anatomic insertion of papillary muscles is different in
patients with HCM according to the presence of LV outﬂow
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tract obstruction at rest. We have also shown that non-
obstructive HCM patients have a higher interpapillary angle
than obstructive HCM patients and control subjects. More-
over, we found an inverse correlation between MPMa and
peak instantaneous LV outﬂow tract gradient at rest. These
results show that increased outﬂow tract gradient in HCM
is accompanied by decreases in MPMa, to values similar to
control subjects.
Our results show that, despite the considerable het-
erogeneity in morphology and genetic substrates that
characterize inherited HCM [20], there is a continuous
relation between LV shape and LV outﬂow tract obstruc-
tion. We hypothesize that part of non-obstructive HCM
is a myocardial disease with LV hypertrophy leading to
the modiﬁcation of papillary muscle insertions with an
increase in MPMa, whereas part of obstructive HCM ini-
tially includes a mitral valve abnormality with a decrease
in LVMa. This hypothesis could explain the high preva-
lence of late gadolinium enhancement in patients with
non-obstructive HCM, whereas apparition of late gadolin-
ium enhancement in patients with obstructive HCM would
occur later with myocardial remodelling. Our results
did not allow us to deﬁnitely ﬁnd out if the different
angulations of mitral valve apparatus contributed to LV
outﬂow obstruction, nor whether LV remodelling induced
by increased intraventricular pressure modiﬁed the geom-
etry of mitral annulus in obstructive HCM. However, it
was reported that part of LV hypertrophy observed in HCM
is after-load dependent and reversible after decrease of
LV outﬂow obstruction by alcohol septal ablation [21].
Moreover, the malposition of the papillary muscles and
the mitral apparatus has previously been suspected to
play a fundamental role in systolic anterior motion of
the anterior leaﬂet of the mitral valve by increasing
the leaﬂet and chordal slack [16,19]. We can hypothe-
size that geometric changes in mitral apparatus, including
mitral annulus orientation, could alter the distribution of
tension on mitral leaﬂets and lead to outﬂow obstruc-
tion.
Finally, we found that LVARa was larger in patients
with non-obstructive HCM than in patients with obstruc-
tive HCM and control subjects, but no signiﬁcant correlation
between LVARa and peak instantaneous LV outﬂow tract
gradient at rest was found. These ﬁndings are differ-
ent to those previously reported by Kwon et al., who
described a smaller LVARa in patients with HCM or hyper-
tensive heart disease than in healthy control subjects
[15]. However, as in our study, they reported that LVARa
was larger in non-obstructive than obstructive HCM [15].
They also reported inverse correlations between LVARa and
maximal LV outﬂow tract obstruction at rest; age; basal
end-diastolic interventricular septal thickness and body sur-
face area [15]. These results show that LVARa is dependent
on parameters other than just intramyocardial haemody-
namics; and the small size of our population could explain
the lack of a correlation between intraventricular obstruc-
tion and LVARa. In our sample, there were no differences
between obstructive and non-obstructive HCM patients in
terms of clinical characteristics, maximum LV thickness
and indexed myocardial mass, suggesting that the observed
difference probably depends on LV outﬂow tract obstruc-
tion.
Study limitations
It is now well established that exercise echocardiography
in hypertrophic cardiomyopathy is an important part of
the accurate evaluation of symptomatic patients without
LV outﬂow tract obstruction at rest [13,14]. The effect
of exercise on LV outﬂow obstruction and angles was not
tested in our patients and we can suppose that we have
underestimated the real impact of LV outﬂow tract obstruc-
tion on LV geometry, which introduces a bias into our
classiﬁcation of HCM. Some patients characterized as non-
obstructive HCM on the basis of the absence of obstruction
at rest might have an exercise-induced obstruction. This
and the small size of our sample have probably increased
the variability in our measurements and could explain
the overlap in the groups and the lack of a correlation
between LVARa and LV outﬂow tract obstruction. Further-
more, the dynamic nature of LV obstruction, depending
on charge conditions and inotropism, could explain the
moderated strength of the correlation between angles and
peak instantaneous LV outﬂow gradient. However, despite
these limitations, our results clearly demonstrate a differ-
ence in LV shape between both entities of HCM. Lastly,
we decided to measure angles in end-diastole and we
did not study the dynamic changes of mitral appara-
tus during the cardiac cycle. However, this has recently
been claimed, in a three-dimensional echocardiographic
study, to have an impact on LV outﬂow tract obstruction
[22].
Potential clinical implications
Better understanding of the pathophysiogenesis of HCM is
the ﬁrst step to improving the care strategy. The anatomy
of the mitral apparatus should be integrated into the global
comprehension of the complex and probably multifactorial
pathophysiogenesis of the systolic anterior motion of the
mitral valve and LV outﬂow tract obstruction in patients
with obstructive HCM. The incomplete resolution of LV out-
ﬂow tract obstruction after surgical myectomy or alcohol
septal ablation [23,24], as well as the high incidence of
persistent systolic anterior motion of the mitral valve after
septal ablation [25], should lead us to reconsider other tar-
gets in the therapeutic management of obstructive HCM,
especially in the surgical ﬁeld. Recent descriptions of new
surgical techniques and concepts, such as papillary muscle
realignment [26], are likely to be very promising axes of
research.
Conclusions
Patients with obstructive HCM display smaller LV to mitral
plane angles than non-obstructive HCM and healthy control
subjects, whereas the insertion angle between the papil-
lary muscles and the LV to aortic root angle are greater in
non-obstructive HCM than obstructive HCM and healthy con-
trol subjects. These ﬁndings highlight the relation between
morphological and functional parameters in HCM, within
which the mitral valve is probably part of pathophysiogene-
sis.
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